Wuhan General Group Updates on University of Pretoria Research Collaboration for Psilocybin Magic Mushroom Clinical Trials
Wuhan General Group announced a research collaboration with the University of Pretoria for psilocybin studies. The project, led by Sanah M. Nkadimeng, aims to explore the effects of psilocybin on depression and cardiovascular risks. Initial studies have shown anti-inflammatory effects, with further in vivo and human studies planned. CEO Jeff Robinson expressed excitement over the findings and future potential. The growing acceptance of psychedelics presents opportunities for investors, paralleling trends in the cannabis sector.
- Research collaboration with University of Pretoria set for psilocybin studies.
- Initial studies indicate anti-inflammatory effects of psilocybin.
- Plans for further in vivo and human studies indicate progress and commitment.
- None.
CAPE TOWN, SA / ACCESSWIRE / October 29, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:
The company's subsidiary MJ Medtech is pleased to announce it has formalized and executed a research collaboration and funding agreement with the University of Pretoria, South Africa, as it relates to ongoing psilocybin magic mushroom research project. The research is being headed up by Sanah M. Nkadimeng, Ph.D. candidate 2020 at the University of Pretoria.
"While it has been a challenge to progress with research under current funding limitations and the COVID-19 pandemic restrictions, it's very exciting to have the University of Pretoria conducting such extraordinary cutting-edge psychedelic research to co-create knowledge. We are looking forward to a long mutually rewarding relationship with M2Bio Sciences, "said Professor JN Eloff, Founder, Phytomedicine Program of the University of Pretoria.
The Study: "Isolation of psilocybin from the genus of Psilocybe and Panaeolus mushroom extracts and investigating their micro-dosing effects and their underlying mechanisms vis-a-vis depression and the cardiovascular risks in vivo on rats and in vitro on cell lines." (2018-2020)
The study aims to investigate the different phytochemistry effects and physiological properties of psilocybin-containing magic mushroom species from genus Panaeolus and Psilocybe on depression and their underlying cardiac excitability. The cardiovascular properties of psilocybin and magic mushrooms will be investigated in vitro on different human and animal cell lines, and in vivo on animal models.
The anti-inflammatory effects from one study from one of the mushroom types has been completed and the results were published in August. More findings from additional studies have been submitted for review and publication including tests with other magic mushroom species. The in vivo animal studies have been successfully completed.
Protocols for further in vivo animal studies and human studies are now being set and scheduled. The timeline is subject to rules, regulations and restrictions from Covid-19.
"It was almost 2 years ago we announced our entering into the magic mushrooms and psychedelics sector and we have so much incredible science to share from the past and ongoing trials. Sanah and her team have made ground-breaking discoveries leading us to amass a treasure trove of intellectual property (IP). We are very excited for our shareholders and we will be presenting further results as the papers and findings are published." said Wuhan General Group CEO Jeff Robinson.
The recognition and acceptance as to the health benefits that psychedelics can offer are growing rapidly. The same legislative movement witnessed in the cannabis sector these past years is now happening for psychedelic mushrooms. Investors have been demonstrating a very strong appetite and support for the sector with many new successful capital raises having taken place.
"Working with and getting to know Jeff and Dr. Anna has been most rewarding. We share a very deep passion for science and medicine. We are all steadfast in our strong belief that we can find new healthier alternative therapies to treat addiction, depression and other very serious debilitating diseases using psilocybin." said Sanah M. Nkadimeng.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M2Bio Sciences is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
For further information:
Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/613264/Wuhan-General-Group-Updates-on-University-of-Pretoria-Research-Collaboration-for-Psilocybin-Magic-Mushroom-Clinical-Trials
FAQ
What is the focus of Wuhan General Group's recent research collaboration?
What are the initial findings from Wuhan's psilocybin studies?
What future studies are planned by Wuhan General Group?
How is the market responding to psychedelic research initiatives?
Who is leading the psilocybin research at the University of Pretoria?
